A large retrospective cohort study based on data from the U.S. Department of Veterans Affairs addressed the question of whether treatment with the antiviral drug nirmatrelvir within five days of positive SARS-CoV-2 testing reduces the risk of post-acute sequelae of covid disease. Nirmatrelvir was shown to reduce the risk of both long-covid and hospitalization and post-acute death at 180 days.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- HAUSARZT PRAXIS
